Biological Vaccines

Abrysvo

Payments companies reported to CMS as associated with Abrysvo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$4.3Massociated payments (2023-2025)

56,105clinicians with associated payments

5companies reporting

By year

2023 $901K

2024 $1.9M

2025 $1.5M

Payments reported as associated with Abrysvo, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Family Medicine $795K

Family $611K

Pediatric Infectious Diseases $551K

Internal Medicine $542K

Infectious Disease $477K

Obstetrics & Gynecology $337K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Abrysvo

These are the largest totals companies reported as associated with Abrysvo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Larry Anderson	Atlanta, GA	Infectious Disease	$203,526.05
Ruth Carrico	Chicago, IL	Family	$192,212.90
Eric Simoes	Aurora, CO	Pediatric Infectious Diseases	$166,576.58
Octavio Ramilo	Memphis, TN	Pediatric Infectious Diseases	$123,532.76
Jaime Fergie	Corpus Christi, TX	Pediatric Infectious Diseases	$84,849.44
Maria Mejias	Memphis, TN	Pediatric Infectious Diseases	$80,524.60
Arthur Jeng	Sylmar, CA	Infectious Disease	$57,130.28
Bernard Gonik	Detroit, MI	Maternal & Fetal Medicine	$45,146.53
Luis Garcia Barreto	Coamo, PR	Pulmonary Disease	$44,342.47
Zane Saul	Stratford, CT	Infectious Disease	$43,708.69

Prescribed Abrysvo?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.